REVENUES

Product Revenues

The Company’s net revenues consisted of the following for the three and six months ended June 30, 2017 and 2016:



	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Products:
Acetadote	$	1,723,984	$	1,895,199	$	2,989,424	$	3,732,661
Omeclamox-Pak	377,470		641,469		1,022,795		1,401,788
Kristalose	2,901,440		3,626,076		5,288,031		7,243,882
Vaprisol	276,705		421,800		961,253		789,848
Caldolor	1,052,917		631,893		1,865,944		1,703,861
Ethyol	2,091,836		—		5,758,644		—
Other	242,775		198,398		417,791		280,327
Total net revenues	$	8,667,127	$	7,414,835	$	18,303,882	$	15,152,367

Other Revenues

The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.